A sponsor’s injectable lipid lowering drug was in a first-to-market race against two competitors when it launched an eight-protocol, phase III global program. Six protocols were evaluating the LDL-C lowering efficacy, safety, and tolerability of the drug, and two studies were investigating its ability to reduce major cardiovascular events.
Acurian reads the pulse of CV studies.
We create a rhythm that will keep your trials on time and on budget, using data you can trust. Plus, we have a track record of resuscitating trials losing ground to attrition.
From atrial fibrillation to hypertension and stroke, we put our hearts into every aspect of patient enrollment and retention for these critical indications.
Acurian has recruited and enrolled thousands of patients for more than 60 pharmaceutical
and biotech companies representing over 4,500 research sites.